Baseline national institutes of health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke

Stroke

Volumn 45, Issue 4, 2014, Pages 1059-1063

  Muchada, Marián ^a   Rubiera, Marta ^a   Rodriguez Luna, David ^a   Pagola, Jorge ^a   Flores, Alan ^a   Kallas, Julia ^a   Sanjuan, Estela ^a   Meler, Pilar ^a   Alvarez Sabin, Jose ^a   Ribo, Marc ^a   Molina, Carlos A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; TIME TO TREATMENT;

STROKE; THROMBOLYTIC THERAPY; TIME-TO-TREATMENT; TISSUE-TYPE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 84897433388     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.004307     Document Type: Article

References (22)

1. Zhang Y, Chapman AM, Plested M, Jackson D, Purroy F. The incidence, prevalence, and mortality of stroke in France, Germany, Italy, Spain, the UK and the US: A literature review. Stroke Res Treat. 2012;2012:436125.
2. Hill MD, Kenney C, Dzialowski I, Boulanger JM, Demchuk AM, Barber PA, et al; Calgary Stroke Program. Tissue Window in Stroke Thrombolysis study (TWIST): A safety study. Can J Neurol Sci. 2013;40:17-20.
3. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
4. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
5. Mishra NK, Lyden P, Grotta JC, Lees KR; VISTA Collaborators. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: A comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010;41:2612-2617.
6. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
7. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
8. Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): Additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095-1102.
9. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
10. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al; SITS investigators. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: An updated analysis from SITS-ISTR. Lancet Neurol. 2010;9:866-874.
11. Ogata T, Christensen S, Nagakane Y, Ma H, Campbell BC, Churilov L, et al EPITHET and DEFUSE Investigators. The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset: Post hoc case-control study. Stroke. 2013;44:87-93.
12. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000;31:1812-1816.
13. Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, et al; VISTA collaborators; SITS collaborators. Thrombolysis in very elderly people: Controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ. 2010;341:c6046.
14. Martins SC, Friedrich MA, Brondani R, de Almeida AG, de Araújo MD, Chaves ML, et al. Thrombolytic therapy for acute stroke in the elderly: An emergent condition in developing countries. J Stroke Cerebrovasc Dis. 2011;20:459-464.
15. Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Delgado P, Montaner J, et al. Tandem internal carotid artery/middle cerebral artery occlusion: An independent predictor of poor outcome after systemic thrombolysis. Stroke. 2006;37:2301-2305.
16. Arenillas JF, Ispierto L, Millán M, Escudero D, Pérez de la Ossa N, Dorado L, et al. Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke. Neurology. 2008;71:190-195.
17. Paliwal PR, Ahmad A, Shen L, Yeo LL, Loh PK, Ng KW, et al. Persistence of hyperdense middle cerebral artery sign on follow-up CT scan after intravenous thrombolysis is associated with poor outcome. Cerebrovasc Dis. 2012;33:446-452.
18. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25:2220-2226.
19. Tsivgoulis G, Sharma VK, Lao AY, Malkoff MD, Alexandrov AV. Validation of transcranial Doppler with computed tomography angiography in acute cerebral ischemia. Stroke. 2007;38:1245-1249.
20. Tsivgoulis G, Sharma VK, Hoover SL, Lao AY, Ardelt AA, Malkoff MD, et al. Applications and advantages of power motion-mode Doppler in acute posterior circulation cerebral ischemia. Stroke. 2008;39:1197-1204.
21. Tsivgoulis G, Ribo M, Rubiera M, Vasdekis SN, Barlinn K, Athanasiadis D, et al. Real-Time validation of transcranial Doppler criteria in assessing recanalization during intra-Arterial procedures for acute ischemic stroke: An international, multicenter study. Stroke. 2013;44:394-400.
22. Burgin WS, Malkoff M, Felberg RA, Demchuk AM, Christou I, Grotta JC, et al. Transcranial Doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke. 2000;31:1128-1132.